Mabwell Bioscience Initiates Phase Ib/II Study for Nectin-4 Targeting ADC 9MW2821
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced the first...
Cancer
BioTroy Therapeutics Receives US FDA IND Approval for Anti-Tumor Drug BT02
BioTroy Therapeutics, a Shanghai-based developer of cancer immunotherapies, has announced the receipt of Investigational New...
Sichuan Kelun-Biotech’s KL-A167 and SKB264 Gain Tacit Clinical Trial Approval in China
The Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...
EC Approves AbbVie’s Tepkinly for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its bispecific...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Two Cancer Drug Candidates
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Novartis’ Lutathera Meets Primary Endpoint in Phase III Trial for GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that a Phase III trial for its...
Abbisko Therapeutics Gets NMPA Approval for Irpagratinib Combination Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has received approval from the National...
Abbisko Therapeutics’ Irpagratinib Receives FDA Clearance for Phase I Study in HCC
Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Fosun Pharma’s Serplulimab Approved for Esophageal Squamous Cell Carcinoma and Grafalon for GvHD Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has issued updates on the development statuses...
MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...
Betta Pharmaceuticals’ CFT8919 Accepted for Review by China’s NMPA for EGFR L858R Solid Tumors
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a China-based pharmaceutical company, has announced that the National...
I-Mab Regains Global Rights to CD47 Antibody Lemzoparlimab Following AbbVie Deal Termination
China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has received a notice from US-based AbbVie Global Enterprises...
Amgen Launches Global Collaboration Network to Advance Oncology Research
Amgen (NASDAQ: AMGN) has announced the launch of a new collaboration network that connects its...
Roche’s Genentech Partners with Orionis Biosciences for Molecular Glue Therapies
Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has announced a partnership with...
Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement
Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm...
Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery
German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...
China’s NHC Expands Rare Disease List, Includes 21 Cancer Types
The National Health Commission (NHC) of China has released an updated national list of rare...
Jiangsu Yahong’s Cevira Meets Primary Endpoint in Phase III Cervical HSIL Study
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, has...
GSK’s Ojjaara Approved by FDA for Anemic Myelofibrosis Patients
The US Food and Drug Administration (FDA) has granted regulatory approval to GlaxoSmithKline (GSK; NYSE:...
Eli Lilly Partners with Boundless Bio to Develop CHK1 Inhibitor for Solid Tumors
Eli Lilly (NYSE: LLY) has announced a partnership with precision oncology specialist Boundless Bio to...